Please assess the completion status of the following clinical trial:

Trial Title: Vaginal Estriol in Multiple Sclerosis

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Female patients with RRMS over the age of 40 to 65.~   * Being prescribed vaginal estriol to treat their urogenital symptoms such as frequency, urgency, incontinence and frequent urinary tract infections.~  * Patients that had underwent chemical or surgical hysterectomy.~2. Patients will continue their current disease modifying agent for MS during the trial.~Exclusion Criteria:~1. Patients with history of breast cancer, uterine or ovarian cancer.~2. Patients with progressive multiple sclerosis~3. Patients who are unable to undergo an MRI~4. Males~5. Patient is already on vaginal or oral or transdermal estrogens~6. Pregnant or breast-feeding patients~7. Patient taking sex hormones eg testosterone for libido~8. Patients taking DHEA or OTC related products that could influence the hormonal milieu.~9. Patient with prolapse uterus or conditions that would impact on transvaginal absorption of estriol

- Gender: FEMALE
- Minimum Age: 40 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- urogenital symptoms (Type: OTHER): To evaluate the efficiency of vaginal estriol, as a treatment for urogenital symptoms in female patients with RRMS.
- remyelination (Type: EXPERIMENTAL): To evaluate the potential role of vaginal estriol in re-myelination in RRMS patients.

Based on this trial design, predict the completion outcome and termination type (if applicable).